Melissa Esgro2021-10-13T13:55:05-04:00 Government Exclusion and Anti-Kickback Controls in the New Era of Co-Pay Assistance
cpalacio2021-08-26T10:26:23-04:00 TC Synapse: TrialCard’s Approach to Risk Mitigation for Manufacturer Programs
Melissa Esgro2021-05-26T14:09:06-04:00 Diversity, Equity, and Inclusion: A Conversation With TrialCard
Melissa Esgro2021-05-05T16:50:14-04:00 Pharmaceutical Sales Strategies Post COVID-19: The Benefits of Virtual Engagement
Melissa Esgro2021-03-11T14:36:23-05:00 Understanding the CMS Best Price Rule and Its Impact to Co-Pay Programs
cpalacio2021-06-10T10:24:34-04:00 Dissecting the CMS Best Price Rule: What it Means for Manufacturer Co-Pay Programs
cpalacio2021-03-07T06:38:48-05:00 The Evidence is In: Integrated Hub and Co-Pay Services Really Do Yield Better Results
cpalacio2021-05-26T08:06:46-04:00 Using Digital Engagement to Solve Pain Points Along the Patient Journey
cpalacio2021-05-26T08:06:45-04:00 Understanding Implications of Proposed Best Price Revisions for Manufacturer Assistance Programs
Kevin Brasco2021-03-07T06:41:56-05:00 Detecting Pharmacy Fraud: Is Your Brand’s Co-Pay Program Protected?
Kevin Brasco2021-03-07T06:42:52-05:00 Co-Pay Accumulator Programs: New Battle or Just Another Front in a Never-Ending War?
Kevin Brasco2021-03-07T06:43:05-05:00 Accumulator Adjustment Programs: What They Are, What They Are Not, and How Should an Affected Health Plan Member Respond?
Kevin Brasco2021-03-07T06:44:17-05:00 Co-Pay Accumulators: Measuring the Impact on Patients and Pharmaceutical Manufacturers
Kevin Brasco2021-03-07T06:44:13-05:00 Examining the Financial Implications of Co-Pay Accumulator Plans
Kevin Brasco2021-03-07T06:44:43-05:00 Integrating Engagement and Adherence Solutions with Affordability Programs
Kevin Brasco2021-03-07T06:44:54-05:00 The Benefits of Integrating Adherence and Engagement Into Co-Pay and Hub Programs
